INSM
INSMED Inc
NASDAQ · Healthcare · Biotechnology · US
$120.00
−3.21%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$123.64
From 52W high−43.24%
Volume3.42M
Market cap$26.21B
P/E (TTM)—
P/S (TTM)23.0x
Div yield—
Key dataSep 18, 2026
Open
$123.64
From 52W high
−43.24%
Volume
3.42M
Market cap
$26.21B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−33.3x
P/E (TTM)
—
RSI (14)
47.6
MomentumView details →
1D Return
−3.21%
YTD Return
−30.35%
SummaryUpdated Jun 1, 2026
Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company founded in 1988 and headquartered in Bridgewater, New Jersey. The company has evolved from its early days to become a specialized developer and commercializer of therapies for patients with serious and rare diseases, particularly focusing on respiratory conditions. Insmed went public in 2000 and has built its business around innovative drug delivery technologies and treatments for orphan diseases with significant unmet medical needs.
Similar companies
Latest newsMore news →
Japan's Ministry of Health, Labour and Welfare approved Insmed's BRINSUPRI (brensocatib) for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12 years and older.27d agoInsmed reported second-quarter 2026 financial results with total revenues of $425.5 million, including BRINSUPRI revenues of $309.2 million and ARIKAYCE revenues of $116.3 million, and raised its 2026 BRINSUPRI revenue guidance to $1.25 billion to $1.40 billion while reiterating ARIKAYCE guidance of $450 million to $470 million.45d agoInsmed Incorporated reported 12-month results from the open-label extension study of its inhaled drug TPIP in pulmonary arterial hypertension patients.66d ago